<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37426952</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Long COVID Clinical Phenotypes up to 6 Months After Infection Identified by Latent Class Analysis of Self-Reported Symptoms.</ArticleTitle><Pagination><StartPage>ofad277</StartPage><MedlinePgn>ofad277</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofad277</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofad277</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The prevalence, incidence, and interrelationships of persistent symptoms after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vary. There are limited data on specific phenotypes of persistent symptoms. Using latent class analysis (LCA) modeling, we sought to identify whether specific phenotypes of COVID-19 were present 3 months and 6 months post-infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This was a multicenter study of symptomatic adults tested for SARS-CoV-2 with prospectively collected data on general symptoms and fatigue-related symptoms up to 6 months postdiagnosis. Using LCA, we identified symptomatically homogenous groups among COVID-positive and COVID-negative participants at each time period for both general and fatigue-related symptoms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among 5963 baseline participants (4504 COVID-positive and 1459 COVID-negative), 4056 had 3-month and 2856 had 6-month data at the time of analysis. We identified 4 distinct phenotypes of post-COVID conditions (PCCs) at 3 and 6 months for both general and fatigue-related symptoms; minimal-symptom groups represented 70% of participants at 3 and 6 months. When compared with the COVID-negative cohort, COVID-positive participants had higher occurrence of loss of taste/smell and cognition problems. There was substantial class-switching over time; those in 1 symptom class at 3 months were equally likely to remain or enter a new phenotype at 6 months.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">We identified distinct classes of PCC phenotypes for general and fatigue-related symptoms. Most participants had minimal or no symptoms at 3 and 6 months of follow-up. Significant proportions of participants changed symptom groups over time, suggesting that symptoms present during the acute illness may differ from prolonged symptoms and that PCCs may have a more dynamic nature than previously recognized. <b>Clinical Trials Registration.</b>&#x2003;NCT04610515.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gottlieb</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3276-8375</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spatz</LastName><ForeName>Erica S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Huihui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wisk</LastName><ForeName>Lauren E</ForeName><Initials>LE</Initials><Identifier Source="ORCID">0000-0003-2932-4140</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmore</LastName><ForeName>Joann G</ForeName><Initials>JG</Initials><Identifier Source="ORCID">0000-0002-7311-6835</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gentile</LastName><ForeName>Nicole L</ForeName><Initials>NL</Initials><Identifier Source="ORCID">0000-0002-9548-7012</Identifier><AffiliationInfo><Affiliation>Post-COVID Rehabilitation and Recovery Clinic, Department of Family Medicine, Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Mandy</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9778-358X</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, UTHealth, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huebinger</LastName><ForeName>Ryan M</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0002-9448-5744</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, UTHealth, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idris</LastName><ForeName>Ahamed H</ForeName><Initials>AH</Initials><Identifier Source="ORCID">0000-0001-7113-6499</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kean</LastName><ForeName>Efrat R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shu-Xia</ForeName><Initials>SX</Initials><AffiliationInfo><Affiliation>Yale Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8383-3854</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Informatics Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montoy</LastName><ForeName>Juan Carlos C</ForeName><Initials>JCC</Initials><Identifier Source="ORCID">0000-0001-7438-0243</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichol</LastName><ForeName>Graham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Departments of Medicine and Emergency Medicine, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Laughlin</LastName><ForeName>Kelli N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Departments of Emergency Medicine and Global Health, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plumb</LastName><ForeName>Ian D</ForeName><Initials>ID</Initials><Identifier Source="ORCID">0000-0003-4747-381X</Identifier><AffiliationInfo><Affiliation>National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rising</LastName><ForeName>Kristin L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0003-3882-4956</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Connected Care, Sidney Kimmel Medical School, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santangelo</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saydah</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ralph C</ForeName><Initials>RC</Initials><Identifier Source="ORCID">0000-0001-5382-9486</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Arjun</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8248-0567</Identifier><AffiliationInfo><Affiliation>Yale Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephens</LastName><ForeName>Kari A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Departments of Family Medicine, Biomedical Informatics and Medical Education, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-3390-858X</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Cook County Hospital, Chicago, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The CORE Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>INSPIRE Group </CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04610515</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cluster</Keyword><Keyword MajorTopicYN="N">phenotype</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. M. G. reports funding from the Rush Center for Emerging Infectious Diseases Research Grant, Emergency Medicine Foundation/Council of Residency Directors in Emergency Medicine Education Research Grant, Emergency Medicine: Reviews and Perspectives Medical Education Research Grant, University of Ottawa Department of Medicine Education Grant, and Society of Directors of Research in Medical Education Grant. E. S. S. receives grant funding from the National Institute on Minority Health and Health Disparities (U54MD010711-01), the US Food and Drug Administration to support projects within the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI, U01FD005938), the National Institute of Biomedical Imaging and Bioengineering (R01EB028106-01), and the National Heart, Lung, and Blood Institute (R01HL151240). J. G. E. reports serving as Editor-in-Chief of Adult Primary Care topics for UpToDate. N. L. G. receives grant funding from the CDC (BAA75D301-20-75D30121C10207). A. V. reports funding for COVID-19&#x2013;related studies from the Society of Academic Emergency Medicine Foundation Emerging Infectious Disease and Preparedness Grant, the Agency for Healthcare Research and Quality (R01 HS 28340-01), the Food and Drug Administration (ID: 75F40120C00174), and the Centers for Medicare and Medicaid Services. G. N. reports the following: funding for COVID-19&#x2013;related studies from the National Institute of Allergy and Infectious Diseases (NIAID) (1R01AI66967), research funding from Abiomed, Vapotherm, and ZOLL Medical; consultant to CPR Therapeutics, Heartbeam Inc, Invero Health LLC, Kestra Medical Technologies, Orixha, and ZOLL Circulation; and reports a patent (Method for non-imaging ultrasound to measure blood flow during CPR) and nonprovisional patent (Method for modifying cell injury associated with reduced blood flow). K. N. O. reports funding for COVID-19&#x2013;related studies from NIAID (1R01AI66967). K. L. R. reports funding for COVID-19&#x2013;related studies from NIAID (1R01AI66967) and the Philadelphia Department of Public Health. All other authors report no potential conflicts.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gottlieb</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santangelo</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koo</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Derden</LastName><ForeName>Antonia</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gottlieb</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gatling</LastName><ForeName>Kristyn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guzman</LastName><ForeName>Diego</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaadan</LastName><ForeName>Marshall</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassaballa</LastName><ForeName>Minna</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jerger</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Zohaib</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choi</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Arjun</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spatz</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Zhenqiu</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Shu-Xia</ForeName><Initials>SX</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Huihui</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Mengni</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Arjun</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spatz</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kinsman</LastName><ForeName>Jeremiah</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dorney</LastName><ForeName>Jocelyn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierce</LastName><ForeName>Senyte</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Puente</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nichol</LastName><ForeName>Graham</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephens</LastName><ForeName>Kari</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morse</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maat</LastName><ForeName>Zenoura</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stober</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Laughlin</LastName><ForeName>Kelli N</ForeName><Initials>KN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gentile</LastName><ForeName>Nikki</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geyer</LastName><ForeName>Rachel E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willis</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malone</LastName><ForeName>Kerry</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Jasmine</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rising</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kean</LastName><ForeName>Efrat</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelly</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaeffer</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hannikainen</LastName><ForeName>Paavali</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shughart</LastName><ForeName>Lindsey</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shughart</LastName><ForeName>Hailey</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renzi</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amadio</LastName><ForeName>Grace</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grau</LastName><ForeName>Dylan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watts</LastName><ForeName>Phillip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miao</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shutty</LastName><ForeName>Carly</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charlton</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hill</LastName><ForeName>Mandy</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chavez</LastName><ForeName>Summer</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kane</LastName><ForeName>Arun</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nikonowicz</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Idris</LastName><ForeName>Ahamed H</ForeName><Initials>AH</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDonald</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallegos</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Riley</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elmore</LastName><ForeName>Joann</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wisk</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>L'Hommedieu</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chandler</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eguchi</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roldan</LastName><ForeName>Kate Diaz</ForeName><Initials>KD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villegas</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moreno</LastName><ForeName>Raul</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodrigue</LastName><ForeName>Robertz</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Ralph C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montoy</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kemball</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chavez</LastName><ForeName>Cecilia Lara</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arreguin</LastName><ForeName>Mireya</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>5</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37426952</ArticleId><ArticleId IdType="pmc">PMC10327879</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofad277</ArticleId><ArticleId IdType="pii">ofad277</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hirschtick JL, Titus AR, Slocum E, et al. . Population-based estimates of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) prevalence and characteristics. Clin Infect Dis 2021; 73:2055&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8240848</ArticleId><ArticleId IdType="pubmed">34007978</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open 2021; 4:e2111417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. . Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 2021; 4:e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler CX, Wyller VBB, Moss-Morris R, et al. . Long COVID and post-infective fatigue syndrome: a review. Open Forum Infect Dis 2021; 8:ofab440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8496765</ArticleId><ArticleId IdType="pubmed">34631916</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention . Long COVID or Post-COVID conditions. 2022. Available at: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Accessed 18 December 2022.</Citation></Reference><Reference><Citation>
World Health Organization . A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 18 December 2022.</Citation></Reference><Reference><Citation>
National Institute for Health and Care Excellence . COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188]. 2020. Available at: https://www.nice.org.uk/guidance/NG188. Accessed 18 December 2022.</Citation></Reference><Reference><Citation>Spatz ES, Gottlieb M, Wisk LE, et al. . Three-month symptom profiles among symptomatic adults with positive and negative SARS-CoV-2 tests: a prospective cohort study from the INSPIRE group. Clin Infect Dis 2023; 76:1559&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11361781</ArticleId><ArticleId IdType="pubmed">36573005</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zang C, Xu Z, et al. . Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med 2023; 29:226&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators; Wulf Hanson S, Abbafati C, Aerts JG, et al. . Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 2022; 328:1604&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny G, McCann K, O&#x2019;Brien C, et al. . Identification of distinct long COVID clinical phenotypes through cluster analysis of self-reported symptoms. Open Forum Infect Dis 2022; 9:ofac060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8900926</ArticleId><ArticleId IdType="pubmed">35265728</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Kelly JD, Lu S, et al. . Persistence, magnitude, and patterns of postacute symptoms and quality of life following onset of SARS-CoV-2 infection: cohort description and approaches for measurement. Open Forum Infect Dis 2021; 9:ofab640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755302</ArticleId><ArticleId IdType="pubmed">35106317</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Laughlin KN, Thompson M, Hota B, et al. . Study protocol for the innovative support for patients with SARS-COV-2 infections registry (INSPIRE): a longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection. PLoS One 2022; 17:e0264260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893622</ArticleId><ArticleId IdType="pubmed">35239680</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner D, Nisenbaum R, Heim C, Jones JF, Unger ER, Reeves WC. Psychometric properties of the CDC symptom inventory for assessment of chronic fatigue syndrome. Popul Health Metr 2005; 3:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183246</ArticleId><ArticleId IdType="pubmed">16042777</ArticleId></ArticleIdList></Reference><Reference><Citation>Geiser C. Data analysis with Mplus. New York: Guilford Press, 2013.</Citation></Reference><Reference><Citation>Oberski D. Mixture models: latent profile and latent class analysis. In: Robertson J, Kaptein M, eds. Modern statistical methods for HCI. Cham: Springer International Publishing, 2016:275&#x2013;87.</Citation></Reference><Reference><Citation>Lanza ST, Collins LM, Lemmon DR, Schafer JL. PROC LCA: a SAS procedure for latent class analysis. Struct Equ Modeling 2007; 14:671&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785099</ArticleId><ArticleId IdType="pubmed">19953201</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins LM, Lanza ST. Latent class and latent transition analysis: with applications in the social behavioral, and health sciences. Hoboken, NJ: Wiley, 2010.</Citation></Reference><Reference><Citation>Wisk LE, Gottlieb M, Spatz ES, et al. . Association of initial SARS-CoV-2 test positivity with patient-reported well-being 3 months after a symptomatic illness. JAMA Netw Open 2022; 5:e2244486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9716377</ArticleId><ArticleId IdType="pubmed">36454572</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien KK, Brown DA, McDuff K, et al. . Conceptualising the episodic nature of disability among adults living with long COVID: a qualitative study. BMJ Glob Health 2023; 8:e011276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9979585</ArticleId><ArticleId IdType="pubmed">36863719</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziauddeen N, Gurdasani D, O&#x2019;Hara ME, et al. . Characteristics and impact of long Covid: findings from an online survey. PLoS One 2022; 17:e0264331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903286</ArticleId><ArticleId IdType="pubmed">35259179</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V-T, Porcher R, Pane I, Ravaud P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun 2022; 13:1812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8983754</ArticleId><ArticleId IdType="pubmed">35383197</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya Y, Alameer A, Calpin G, Alkhattab M, Sultan S. A comprehensive review of vascular complications in COVID-19. J Thromb Thrombolysis 2022; 53:586&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8558544</ArticleId><ArticleId IdType="pubmed">34724155</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med 2022; 28:911&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Yang D, Medicherla C, et al. . Trajectories of neurologic recovery 12 months after hospitalization for COVID-19: a prospective longitudinal study. Neurology 2022; 99:e33&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9259089</ArticleId><ArticleId IdType="pubmed">35314503</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellmuth J, Barnett TA, Asken BM, et al. . Persistent COVID-19&#x2013;associated neurocognitive symptoms in non-hospitalized patients. J Neurovirol 2021; 27:191&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7852463</ArticleId><ArticleId IdType="pubmed">33528824</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Sillett R, Zhu L, et al. . Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1&#x2008;284&#x2008;437 patients. Lancet Psychiatry 2022; 9:815&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Mart&#xed;n-Guerrero JD, Navarro-Pardo E, Cancela-Cilleruelo I, Moro-L&#xf3;pez-Menchero P, Pellicer-Valero OJ. Exploring trajectory curves from loss of smell and taste in previously hospitalized COVID-19 survivors: the LONG-COVID-EXP-CM multicenter study. J Gen Intern Med 2022; 37:1821&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863099</ArticleId><ArticleId IdType="pubmed">35194745</ArticleId></ArticleIdList></Reference><Reference><Citation>Horberg MA, Watson E, Bhatia M, et al. . Post-acute sequelae of SARS-CoV-2 with clinical condition definitions and comparison in a matched cohort. Nat Commun 2022; 13:5822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556630</ArticleId><ArticleId IdType="pubmed">36224218</ArticleId></ArticleIdList></Reference><Reference><Citation>
Perrin A, Turner E. Smartphones help blacks, Hispanics bridge some&#x2014;but not all&#x2014;digital gaps with whites.2019. Available at: https://policycommons.net/artifacts/616650/smartphones-help-blacks-hispanics-bridge-some/1597318/. Accessed 18 December 2022.</Citation></Reference><Reference><Citation>Vihta KD, Pouwels KB, Peto TE, et al. . Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. Clin Infect Dis 2022; 76:e133&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384604</ArticleId><ArticleId IdType="pubmed">35917440</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Polidori L, et al. . Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of Omicron and Delta variant dominance: a prospective observational study from the ZOE COVID study. Lancet 2022; 399:1618&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang RC, Gottlieb M, Montoy JC, et al. . Association between SARS-CoV-2 variants and frequency of acute symptoms: analysis of a multi-institutional prospective cohort study - December 20, 2020 &#x2013; June 20, 2022. Open Forum Infect Dis 2023. doi: 10.1093/ofid/ofad275</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad275</ArticleId><ArticleId IdType="pmc">PMC10327880</ArticleId><ArticleId IdType="pubmed">37426947</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb M, Wang RC, Yu H, et al. . Severe fatigue and persistent symptoms at 3 months following Severe Acute Respiratory Syndrome Coronavirus 2 infections during the pre-Delta, Delta, and Omicron time periods: a multicenter prospective cohort study. Clin Infect Dis 2023; 76:1930&#x2013;41. doi: 10.1093/cid/ciad045</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad045</ArticleId><ArticleId IdType="pmc">PMC10249989</ArticleId><ArticleId IdType="pubmed">36705268</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>